Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMTX-101 in Cystic Fibrosis with Pseudomonas Aeruginosa Infection
NCT06159725Phase 2Completed
- Sponsor
- Clarametyx Biosciences
- Start
- Jun 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of CMTX-001 in Pseudomonas aeruginosa infection (4 arms), sponsored by Clarametyx Biosciences. Primary endpoints: Adverse Events and Serious Adverse Events. Started Jun 2024; status: completed.
02
Drugs
CMTX-001
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT06159725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159725.